Photocure ASA (0IMT) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

All right, well, welcome to PhotoCure's third quarter 2025 results. I'm Dan Schneider, President and CEO, and with me today is Eric Dahl, our CFO. A reminder, the usual disclaimers are in effect for today's presentation. So I'd like to start with this slide, the strategic priorities and initiatives. It's our guide to how we execute and allocate resources across the company. At a high level, our strategy is centered around three key pillars, strengthening the core HEXFIX SysView business, advancing blue light cystoscopy as a definitive standard of care in bladder cancer, and expanding our reach into the broader uro-oncology and precision diagnostic space. The first pillar, accelerate and expand, is about delivering on our financial guidance for disciplined growth in revenue and EBITDA in our core business and to continue generating operating leverage, which we continue to do so. It's also about driving the blue light cystoscopy mobile strategy for tech in the U.S. and increasing penetration in the EU, particularly in the priority growth markets, France, Italy, U.K., through blue light expansion and the image upgrades, most recently Viscera 3 by Olympus. And thirdly, expanding a geographic footprint and leveraging our distribution partnerships across the globe. In the second pillar, positioning and access, we're building on the foundations of BLC as a primary precision diagnostic. And you watch throughout today's presentation, I talk often about precision diagnostics in this space that's exploding. As a tool to facilitate early and appropriate use of non-muscle invasive bladder cancer, the detection, the surveillance, and the therapeutic monitoring. Inclusives of life cycle management is demonstrated by our recent strategic collaboration to develop the world's first an...